KA News & Events

Kineta (KA) announced that it has completed the enrollment of new patients into the monotherapy arm of the VISTA-101 phase 1 clinical trial evaluating KVA12123, Kineta's novel VISTA blocking immunotherapy, in patients with advanced solid tumors. The monotherapy portion of the trial enrolled patients in 6-dose cohorts ranging from 3mg to 1000mg every two weeks and no dose limiting toxicities or cytokine related adverse events have been observed in the study. The Company is continuing to enroll patients into cohorts evaluating KVA12123 in combination with Merck's (MRK) anti-PD-1 therapy, KEYTRUDA.

Kineta has transitioned from Nasdaq to the OTC Market. Kineta stock now trades under the ticker symbol "KANT" on the OTC Pink Open Market platform. This transition went into effect at the beginning of trading on September 19. Kineta had previously received a notice from Nasdaq that it had determined to delist the company's common stock from Nasdaq due to the company's failure to satisfy the $1.00 minimum bid price listing requirement and failure to maintain a minimum of $2,500,000 in stockholders' equity. Shareholders will not need to take any action.